Zheng Quan Ri Bao·2026-01-30 23:13Core Viewpoint - The company expects a significant decline of over 50% in net profit for the year 2025 compared to the previous year, primarily due to a high base effect from one-time investment gains in the prior period [1][2]. Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025, with an anticipated positive net profit but a substantial decrease [1]. - The company has communicated with its accounting firm regarding the performance forecast, and there are no discrepancies between the two parties [1]. Reasons for Performance Changes - The group has seen significant growth in the global heparin market, with steady sales performance across regions and a continuous increase in market share, particularly with double-digit growth in enoxaparin sales [2]. - The decline in net profit attributable to shareholders is mainly due to a one-time investment gain exceeding RMB 350 million in the same period last year, creating a high comparative base [2]. - Despite the expected impact from joint ventures due to unmet R&D progress, the company has achieved growth in net profit after excluding non-recurring gains, driven by steady increases in main business revenue and profit [2]. Other Relevant Information - The performance forecast is based on preliminary calculations by the company's finance department, and specific financial data will be confirmed in the 2025 annual report [3].